Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) EBT Margin (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed EBT Margin for 14 consecutive years, with 64.0% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 6989.0% year-over-year to 64.0%, compared with a TTM value of 108.62% through Dec 2025, up 5125.0%, and an annual FY2025 reading of 127.9%, up 4625.0% over the prior year.
  • EBT Margin was 64.0% for Q4 2025 at Enanta Pharmaceuticals, up from 123.42% in the prior quarter.
  • Across five years, EBT Margin topped out at 64.0% in Q4 2025 and bottomed at 211.37% in Q1 2023.
  • Average EBT Margin over 5 years is 149.11%, with a median of 149.66% recorded in 2021.
  • The sharpest move saw EBT Margin plummeted -10888bps in 2021, then surged 7638bps in 2025.
  • Year by year, EBT Margin stood at 109.05% in 2021, then decreased by -13bps to 123.04% in 2022, then tumbled by -54bps to 189.02% in 2023, then grew by 29bps to 133.89% in 2024, then skyrocketed by 52bps to 64.0% in 2025.
  • Business Quant data shows EBT Margin for ENTA at 64.0% in Q4 2025, 123.42% in Q3 2025, and 99.52% in Q2 2025.